Pfizer, Astellas win China nod for Padcev in bladder cancer with Merck’s Keytruda
by
Contributor since / Followers
Contributor since / Followers
21 hours ago
solidcolours
- Astellas (OTCPK:ALPMY) (OTCPK:ALPMF) announced Wednesday that Chinese regulators approved its antibody-drug conjugate Padcev, developed with Pfizer (NYSE:PFE), as a first-line treatment combo with Merck’s (NYSE:MRK) Keytruda for a type of bladder cancer.
- Accordingly, Padcev plus Keytruda will be the first non-platinum